Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Seribantumab |
Synonyms | |
Therapy Description |
Seribantumab (SAR256212) is a human monoclonal antibody that binds ERBB3 (HER3) and prevents ligand binding and heterodimerization with other ERBB family members, resulting in decreased activation of downstream signaling and potentially leading to reduced tumor growth (PMID: 26310543, PMID: 30975923). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Seribantumab | MM-121|SAR256212 | HER3 (ERBB3) Antibody 23 | Seribantumab (SAR256212) is a human monoclonal antibody that binds ERBB3 (HER3) and prevents ligand binding and heterodimerization with other ERBB family members, resulting in decreased activation of downstream signaling and potentially leading to reduced tumor growth (PMID: 26310543, PMID: 30975923). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02387216 | Phase II | Seribantumab Pemetrexed Disodium Docetaxel | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | Terminated | USA | HUN | FRA | ESP | DEU | CAN | 0 |
NCT04383210 | Phase II | Seribantumab | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | Terminated | USA | CAN | AUS | 1 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |